Duo-Med Group Belgium agreed to acquire Launch Diagnostics Holdings Limited from Avacta Group Plc (AIM:AVCT) for £12.9 million on March 7, 2025. A cash consideration of £12.9 million will be paid by Duo-Med Group Belgium. As part of consideration, £12.9 million is paid towards common equity of Launch Diagnostics Holdings Limited. Avacta Group Plc (AIM:AVCT) sold Launch Diagnostics Holdings Limited and its subsidiaries, its UK-based and largest diagnostics unit.

As at 30 June 2024 Launch Diagnostics had unaudited net assets of £13.65 million.

The transaction is subject to customary closing conditions.

The expected completion of the transaction is by the end of April 2025.